Trio of therapies reduces risk of death in patients with severe COVID-19
European Pharmaceutical Review
AUGUST 11, 2022
Hospitalised patients on high-flow oxygen for severe COVID-19 pneumonia were nearly 50 percent less likely to die when treated with antiviral remdesivir in combination with steroid dexamethasone and baricitinib, according to research from Rutgers Ernest Mario School of Pharmacy in the US.
Let's personalize your content